Skip to main content
Clinical Trials/NCT04690569
NCT04690569
Completed
N/A

Prospective, Multi-Center, Observational, Blinded Study to Establish the Diagnostic Performance of the MeMed BV™ Test for Differentiating Bacterial From Viral Infection in Patients With Suspected Acute Bacterial or Viral Infection ("APOLLO" STUDY)

MeMed Diagnostics Ltd.9 sites in 2 countries1,384 target enrollmentMay 3, 2019
ConditionsAcute Infection

Overview

Phase
N/A
Intervention
Not specified
Conditions
Acute Infection
Sponsor
MeMed Diagnostics Ltd.
Enrollment
1384
Locations
9
Primary Endpoint
Establish the diagnostic performance of the MeMed BV™ Test for differentiating bacterial from viral infection using expert adjudication comparator method.
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Prospective, multi-center, observational, blinded study, enrolling pediatric and adult subjects. Eligible ED\Urgent care and hospital admitted patients with symptoms consistent with acute bacterial or viral infection and healthy subjects will be recruited according to the eligibility criteria. Each participant will undergo a thorough investigation upon recruitment that includes documenting clinical, radiological, laboratory and microbiological information for determining their health status.

Follow-up data will be collected via a phone call. Diagnostic performance of the MeMed BV™ Test for differentiating bacterial from viral infection will be assessed using an expert adjudication comparator method.

The study will be run in a blinded fashion: site personnel will be blinded to the comparator method outcomes, and the expert panel will be blinded to the results of the index test. Results of the index test will not be revealed to the attending clinician and so will not influence patient management.

Registry
clinicaltrials.gov
Start Date
May 3, 2019
End Date
November 22, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Written informed consent must be obtained from the patient or his/her legal guardian. For children under 18 years old, written informed consent from the legal guardian and assent from the patient (depending on the local requirements)
  • Over 90 days of age
  • Clinical suspicion of acute bacterial or viral infection
  • Temperature ≥ 37.8°C (100°F) (any body site, any measurement device, including self-reported) or tactile fever, either of them noted at least once within the last 7 days
  • Current disease duration ≤ 7 days

Exclusion Criteria

  • Another unrelated episode of febrile infection within the past 2 weeks
  • Suspicion and/or confirmed diagnosis of infectious gastroenteritis/ colitis
  • \>48 hours of oral antibiotic treatment
  • \>12 hours of intravenous\\intramuscular antibiotic treatment
  • HIV, HBV, or HCV infection (self-declared or known from medical records)
  • A proven or suspected infection on presentation with Mycobacterial (e.g. Tuberculosis, MAC), parasitic or fungal (e.g. Candida, Histoplasma, Aspergillus) pathogen
  • Active inflammatory disease (e.g. IBD, SLE, JIA, RA, Kawasaki, other vasculitis)
  • Major trauma and\\or burns in the last 7 days
  • Major surgery in the last 7 days
  • Congenital immune deficiency (CID)

Outcomes

Primary Outcomes

Establish the diagnostic performance of the MeMed BV™ Test for differentiating bacterial from viral infection using expert adjudication comparator method.

Time Frame: Through study completion, an average of 18 months

Establish the diagnostic performance of the MeMed BV™ Test for differentiating bacterial from viral infection using expert adjudication comparator method.

Study Sites (9)

Loading locations...

Similar Trials